HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

L’Oreal Should Discontinue Ads Due To Post-Production Touch-Ups, Says ASA

This article was originally published in The Rose Sheet

Executive Summary

The Advertising Standards Authority advises L’Oreal to discontinue a pair of magazine ads due to suspicions that images reflect digital retouching more than the merits of the advertised products.

You may also be interested in...



NAD: Photoshopping Okay, But Not When Demonstrating Product Benefits

At the National Advertising Division’s Annual Conference in New York, Director Andrea Levine clarified the advertising watchdog’s position on using post-production techniques in cosmetics advertisements.

ASA Rulings Help Clarify Acceptable Vs. Misleading Post-Production Ad Work

The U.K.’s Advertising Standards Authority examines ads for L’Oreal ParisAge Re-Perfect Pro-Calcium + SPF 15 and Revitalift Repair 10 anti-aging cream, both of which feature models whose photographs were digitally altered to some degree. One of the ads must not run again in its current form, the independent regulator says.

NAD’s Patience For Photoshopping In Beauty Ads May Be Wearing Thin

The National Advertising Division was “troubled” that a model’s lashes were digitally enhanced in a Procter & Gamble ad for CoverGirl NatureLuxe Mousse Mascara. NAD’s position on the firm’s post-production tinkering is consistent with recent decisions from its U.K. counterpart, the Advertising Standards Authority

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS017684

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel